Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.
Pharma & Biotech
Pharma & Biotech
Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
Pharma & Biotech
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Pharma & Biotech
Why Lilly’s LIBRETTO-432 results matter beyond selpercatinib’s event-free survival win
Eli Lilly and Company (Lilly) announced that its selective RET inhibitor selpercatinib, marketed as Retevmo, achieved a highly statistically significant improvement in investigator-assessed event-free survival when used as adjuvant therapy in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, based on topline results from the Phase 3 LIBRETTO-432 trial. The study compared selpercatinib
Pharma & Biotech
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.
Pharma & Biotech
What D3 Bio’s dual KRAS IND clearances reveal about the next wave of targeted oncology
D3 Bio secures U.S. FDA IND clearances for two KRAS programs, advancing G12D monotherapy and G12C resistance combo trials. See what this means for oncology.
Pharma & Biotech
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.
Pharma & Biotech
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
Medical Devices & Diagnostics
What the TRACERx study reveals about Personalis’ MRD technology in NSCLC
Personalis, Inc. has reported pivotal findings from its NeXT Personal assay in a new Cell publication, highlighting the test’s ability to detect molecular residual disease in stage I to III non-small cell lung cancer. The study, part of the TRACERx initiative and led by Professor Charles Swanton of the Francis Crick Institute and University College